What Is Peptide Therapy? The Honest Explanation

A peptide is a short chain of amino acids — the same building blocks as proteins, but shorter. Fewer than two residues and you have an amino acid. Two to fifty and you have a peptide. Past fifty, you're in protein territory.

Your body synthesizes hundreds of peptides and uses them constantly. Insulin is a peptide. Oxytocin is a peptide. The endorphins your nervous system releases after a long run are peptides. So is glucagon, the molecule your liver listens to when your blood sugar drops. This isn't exotic biology — it's the plumbing.

What makes peptides useful from a research standpoint is their specificity. Testosterone, a steroid hormone, touches dozens of tissue types and downstream programs simultaneously. A given peptide tends to bind one receptor family and trigger one cascade. That's a narrower action radius, which is why the science and the risks look different.

There is no single "peptide effect." The category is a collection of distinct molecules with distinct biology — one peptide is not another. Grouping them as if they're interchangeable is the first sign that someone is selling you something.

Yes, when it is prescribed. Therapeutic peptides are not a fringe category. Since insulin entered medicine about a century ago, more than 80 peptide drugs have reached the market, for conditions including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain (Muttenthaler et al., Nature Reviews Drug Discovery, 2021).

A 2022 review of peptide therapeutics credits the field's recent progress to new production, modification, analytic and delivery technologies that have helped overcome the molecules' inherent drawbacks (Wang et al., Signal Transduction and Targeted Therapy, 2022). The drawback a patient notices first is practical: digestion breaks amino acid chains apart, which is why most clinical peptides are injected rather than swallowed.

Are GLP-1 medications peptides?

Yes. Semaglutide and tirzepatide are peptide molecules that act on incretin-hormone receptors (GLP-1, and for tirzepatide, GIP as well). Not every peptide is a GLP-1, though. The large trials behind the branded GLP-1 products do not transfer to other peptides, and they do not transfer to compounded versions either, which are not FDA-approved and were not studied in those trials.

The distinction that matters to a patient is regulatory, not chemical. A peptide prescribed by a physician and dispensed by a licensed pharmacy is a prescription medication. The same molecule sold online as a "research chemical" is not.

A peptide binds to a receptor on a cell surface. The receptor changes shape. That shape change triggers a downstream cascade — gene expression shifts, an enzyme activates, a hormone is released, a repair program engages. The peptide doesn't do the work itself. It's the signal that tells the cell to do the work.

A secretagogue, a peptide that signals your pituitary to release growth hormone, is an example. It does not add a foreign hormone; it amplifies a signal the pituitary already responds to, and the response is limited by what the gland can still produce.

That's the meaningful contrast with hormone replacement therapy: many therapeutic peptides operate upstream of your body's own feedback loops, engaging a receptor that then triggers the body's own production. Not replacing. Signaling.

The diversity of applications follows from this. Growth-hormone-releasing peptides work on pituitary signaling. Others interact with mitochondrial pathways, immune signaling, or central nervous system receptors. The word "peptide" is a shape description, not a category of effect. Mechanism matters. Source matters. Oversight matters.

This part clears up most of the noise in the category.

Anabolic steroids are synthetic testosterone or its analogs. They bind directly to the androgen receptor and add hormone to the body — which, as a downstream consequence, can suppress your own production. That's a different pharmacological action and a different risk profile.

SARMs (selective androgen receptor modulators) bind the same receptor with a more selective profile. None is FDA-approved for any use, and they carry their own set of characterized and uncharacterized risks. (For where the law stands on peptides, see are peptides legal.)

Recombinant HGH is a synthetic protein that acts directly on the growth-hormone axis. Sermorelin, which signals the pituitary to produce its own HGH, is a categorically different molecule operating at a different point in the system.

Therapeutic peptides — the kind a US physician evaluates and may prescribe — are a different class of molecule with different pharmacology. They are not anabolic steroids, they are not SARMs, and they are not recombinant HGH.

They are also not supplements. The supplement aisle operates under a disclosure regime, not an approval regime, which is why the claims on a protein powder look different from the claims on a prescription label. Peptides, when prescribed and dispensed appropriately, are prescription medications inside a clinical model with physician oversight. That matters for what's in the vial, how it's tested, and who's accountable.

This is where the category gets both interesting and easily abused by claims that outrun the evidence. Below is an honest map of the goals physicians discuss peptide therapy for — organized by how well-studied each area is.

Metabolic support

GLP-1 receptor agonists are the most publicly visible example in this space, operating on peptide signaling pathways to affect satiety and glucose metabolism. That class has substantial clinical trial data and FDA-approved products for specific indications. Other peptides in this space, including some growth-hormone secretagogues, have meaningful preclinical data but smaller human study sets. The distinction matters: strong evidence in one corner of the metabolic category doesn't transfer automatically across the whole space.

Recovery and performance

Some peptides have been studied for tissue repair and recovery, primarily in preclinical and smaller-scale models. The research is real; the human trials are thinner than the enthusiast community often acknowledges. Physicians who prescribe in this space are working with the honest caveat that the mechanism is plausible and the early data is interesting — not that the outcome is guaranteed.

Aging, longevity, and sleep

The pituitary secretagogue class — Sermorelin among them — is discussed for supporting the natural decline in growth hormone with age, which tracks across the lifespan beginning in the early thirties. Related research touches sleep architecture and recovery, since GH release is concentrated in slow-wave sleep. This is also where the "peptide therapy for anti-aging" framing gets the most traction — and the most overpromising. Healthspan support is a reasonable goal. Reversing biological age is a marketing line, not a clinical outcome.

Sexual health and cognitive function

Some peptides interact with melanocortin receptors and have been studied for sexual dysfunction. Cognitive-focused applications, including peptides discussed for focus and neuroprotection, are an active area with generally early-stage evidence. These applications are real enough to discuss and preliminary enough to require serious qualification.

Immune modulation

Some peptides have been studied for immune system support, with applications in immune-compromised populations and chronic illness contexts. This is a different clinical population from the performance-and-longevity space, and the evidence base is distinct.

How a peptide gets into your body matters more than most people realize, and it's where a lot of gray-market products quietly fail before the safety question ever comes up.

Subcutaneous injection is the most common route for therapeutic peptides in a clinical program. It delivers the compound into the tissue just below the skin, bypassing the digestive system's tendency to break peptides down before they reach the bloodstream. Sterile technique, proper reconstitution of lyophilized (freeze-dried) peptides, and pharmaceutical-grade sourcing all matter here — this is the point in the chain where a contaminated or mislabeled product causes real harm.

Intranasal delivery is used for some peptides with CNS targets — the nasal mucosa provides a more direct route to the central nervous system than systemic injection. This route is less common in clinical practice but available for specific molecules.

Topical application applies primarily to cosmetic and skincare-adjacent peptides — collagen-supporting peptides in cosmeceuticals, for example. These are a different class from the injectables discussed in a clinical peptide program and operate at the surface level rather than systemically.

Oral peptides are generally a harder delivery problem: the digestive system is very good at breaking amino acid chains apart before they can act systemically. Some formulations address this; most don't. An oral "peptide supplement" making systemic therapeutic claims is, in most cases, making claims the delivery route cannot support.

A legitimate clinical program will specify the route, provide clear reconstitution and injection instructions where applicable, and ensure the medication arrives in a form that's actually compatible with its intended use.

Peptide therapy isn't side-effect-free, and any program that implies otherwise is either uninformed or incurious about the people in it. For the fuller safety picture, see is peptide therapy safe.

The side effect profile varies significantly by molecule. For Sermorelin, a GHRH analog, the most commonly reported effects are injection-site reactions (redness, swelling, minor bruising), flushing and headache. Increased hunger and raised cortisol or prolactin are associated with a different class of growth-hormone secretagogues that mimic ghrelin, not with GHRH analogs like Sermorelin. Effects tied to higher growth-hormone activity, such as transient water retention, joint aches or tingling in the hands, are reasons to report symptoms and for a physician to reconsider the dose.

Some peptides can affect blood sugar regulation, which matters if you're diabetic or pre-diabetic and one more reason why a full medical history matters before any prescription is written. A clinician who doesn't ask about glucose management before prescribing isn't practicing carefully.

The more serious concern isn't usually the mechanism of a well-characterized peptide at a reasonable dose — it's the sourcing. Peptides sold online as research chemicals are not made or tested to prescription standards, and nobody is accountable for what is in the vial. A contaminated or mislabeled injectable carries risks that have nothing to do with the therapeutic molecule: bacterial endotoxins, solvent residue, incorrect concentration, cross-contamination. Those aren't theoretical. That's the real safety calculus for this category.

Physician oversight means someone tracks your response, adjusts the protocol when needed, and stops the program when the data doesn't support continuing. A program that ships product and then disappears isn't managing safety. It's outsourcing it to you.

Here's where a lot of peptide content quietly looks the other way. We're not going to do that, because a patient who understands the evidence hierarchy is a better patient.

The evidence base across this category is genuinely uneven. Molecule by molecule, the research depth varies by an order of magnitude.

Some peptides have FDA-approved branded products for specific, narrowly-defined indications. (A compounded version of that molecule is not the same product and is not FDA-approved. Compounded medications as a category operate under a separate regulatory pathway — prepared by a licensed pharmacy for an individual patient pursuant to a valid prescription.) Others have meaningful preclinical work and smaller human trials but no large registration trials. And some peptides circulating on forums and gray-market sites are investigational, under active FDA review, or not legally available for prescription compounding.

Protocol MD's menu — compounded GLP-1 (semaglutide and tirzepatide), Sermorelin, NAD+, and Glutathione — reflects a deliberate choice to operate within what's currently accessible through compliant prescription channels.* Protocol MD sells these medications, so read this section with that commercial interest in mind. Many molecules discussed enthusiastically online, including some under FDA review, are not part of the offering.

Each therapy we offer has its own deep-dive guide: compounded GLP-1 medication (see semaglutide vs tirzepatide), Sermorelin (the GH-axis peptide), NAD+ (a coenzyme in cellular energy metabolism), and glutathione (the body's main antioxidant).

The standard we apply: a serious program will be candid about where the evidence is solid and where it's thin. It won't generalize, it won't hand you a "stack" and a slogan, and it won't blur the line between well-studied and speculative.

* Protocol MD's current product menu reflects compliance with applicable federal and state regulations as of publication. This is subject to change as the regulatory landscape evolves.

Four steps. Each one matters.

Step 1: Intake and Goal Definition

A clinical questionnaire captures your goal, medical history, current medications, and anything that would change what's appropriate. This isn't a sales funnel — it's the information a clinician needs to decide whether peptides are even the right tool, and if so, which ones.

Step 2: Physician Evaluation

A US-licensed physician reviews the intake. The evaluation may be synchronous or asynchronous depending on the clinical picture. Either way, a real clinician makes the decision. Not an algorithm. A program where every patient gets a prescription is a program worth being suspicious of.

Step 3: 503A Compounded Prescription

If the physician determines a prescription is appropriate, it goes to a 503A compounding pharmacy — state-licensed, required to follow USP standards for compounding. The medication that arrives has your name on it, a beyond-use date and a lot number, and the pharmacy can document the testing behind it.

This chain of custody is the single most important difference between a legitimate program and a Telegram channel.

Step 4: Protocol and Physician-Led Follow-Up

Your physician sets the dose, protocol, and duration. This article does not, and cannot, do those things — that's not a disclaimer, it's the actual point. A serious program provides defined endpoints, planned check-ins, and a clinician who adjusts or stops the plan based on how you respond.

Those four steps are the Protocol MD peptide pathway: an online intake, review by a US-licensed physician, a 503A-compounded prescription only if the physician approves, and follow-up with the prescribing physician as needed. Your card is authorized at checkout and charged only if a physician approves your prescription.

A serious program is built around adults with a clearly defined goal and a willingness to work inside a structured, physician-supervised model. It is not a wellness experiment for someone with no underlying complaint, and it is not a substitute for sleep, training, nutrition, stress management, or ordinary medical care for ordinary problems.

Conditions that commonly rule a patient out — and should cause any legitimate physician to decline — include pregnancy and breastfeeding, active malignancy for growth-hormone-axis therapies like Sermorelin, and a personal or family history of medullary thyroid carcinoma or MEN 2 for GLP-1 medications. A program that never declines anyone isn't practicing medicine.

Whether any of this is appropriate for you is a question a physician answers after your intake. Book a free consult to find out where you stand.

Red flags — walk away

No physician involved. You order a vial from a website with no questionnaire, no clinician, no prescription. That's the research-chemical supply chain, and it operates outside the law governing prescription medicine.

"Not for human use" labeling. That phrase exists to keep regulators off the seller's back. It is a legal shield for the seller, not a statement about what's in the vial.

Pre-packaged stacks. "The Recovery Stack." "The Longevity Bundle." A real plan is decided by a clinician after evaluating a patient — not packaged and sold before anyone has been seen.

No certificate of analysis on request. If you can't see third-party testing for identity, purity, and sterility, you don't know what you're injecting.

No follow-up structure. A program that ships product and then disappears is not a clinical program. It is a shipping operation with a wellness veneer.

Outsized claims. Guarantees, disease-reversal language, "reverses biological age," anything framed as miraculous. The evidence — and the law — require qualification. Legitimate clinicians qualify their statements.

Green flags — keep going

• Licensed clinician evaluation before any prescription is written
• 503A pharmacy compounding with the patient's name on the medication
• A pharmacy that can document identity, potency and sterility testing
• Defined protocol with physician-set endpoint and structured check-ins
• Plain-language discussion of risks, contraindications, and alternatives
• Willingness to decline treatment when inappropriate
• Transparency about which molecules are under FDA review or not available through compliant channels

Peptides occupy genuinely interesting territory: more specific than a supplement, different in mechanism from hormone replacement, built around signaling biology rather than blunt-force substitution.

The same molecule can arrive as a sterile, third-party-tested compound from a 503A pharmacy with a physician's name on the prescription — or as a research-chemical vial labeled "not for human use," sourced from somewhere unverifiable and sold to anyone with a credit card. Telling those two paths apart is the most important practical decision a prospective patient makes.

The biology is real. The interest is legitimate. The gray market is the problem — not because it's illegal, but because "probably fine" is a strange standard for a sterile injectable. Physician oversight, pharmaceutical-grade compounding, and follow-up exist because they change the actual risk profile of a treatment, not because they're paperwork.

None of this is magic. It's signaling, sourcing, and measurement — done by someone whose license is on the line. Learn whether a protocol makes sense for you, or browse our physician-prescribed peptides.

Peptide therapy is the physician-prescribed use of short chains of amino acids to support specific functions in the body: a medical treatment that requires an evaluation and a prescription, not an over-the-counter supplement.